Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM-STOP: Oritavancin and MOUD for Infections in People Who Use Drugs
NCT05521880Phase 4Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- Jul 2024
- Primary completion
- May 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of oritavancin in bacterial infection, skin and soft tissue infection (SSTI), Bacteremia, osteomyelitis (OM), septic arthritis, sponsored by University of Maryland, Baltimore. Started Jul 2024; status: terminated.
02
Drugs
oritavancin
03
Conditions
bacterial infectionskin and soft tissue infection (SSTI)Bacteremiaosteomyelitis (OM)septic arthritis
Beyond the preview
Go deeper on NCT05521880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05521880.